PsiOxus Therapeutics sees industry demand for oncolytic vaccines
The Oxfordshire, UK-based firm, which formed last month through the merger of Myotec Therapeutics and Hybrid Biosystems, develops novel biotechnology-based agents such as, ColoAd1, its candidate viral cancer treatment.
CEO John Beadle told in-PharmaTechnologist.com there is growing pharmaceutical industry interest, highlighting Amgen’s acquisition of BioVex as a key development in the field of oncolytic vaccines.
He explained that: “Current cancer therapies all tend to have the same limitations since they kill cancer cells through the same pathways but by killing cancer cells through an entirely new mechanism, oncolytic vaccines are providing a significant breakthrough.
“The BioVex approach now opens the way for follow-on oncolytic approaches, such as ColoAd1, which can be used systemically as well as through local administration."
